DURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will host a virtual webinar to announce top line data results from its Phase 2/3 V005 vascular trauma clinical trial. The V005 trial evaluated the HAV, an off-the-shelf, universally implantable bioengineered human tissue, in vascular trauma repair. The event will also feature Dr. Michael Curi (Rutgers University), who will discuss the unmet clinical need in vascular trauma, and the use of the HAV as a potential repair solution for patients and soldiers with limb- and life-threatening injuries. Dr. Curi has utilized the HAV and has participated in the V005 clinical trial.
The HAV has received priority designation for the treatment of vascular trauma by the U.S. Department of Defense and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration.
A live question and answer session will follow the formal presentations. Details of the data announcement webinar are as ...